limited amount for drugs annually, with annual caps ranging from $1000 to $20,000. Companies had different payment policies for brand-name drugs and generic drugs. Lifetime benefit maximum for physician office and hospital visit expenses was another form of cap that was used. Assuming no other claims applied, analysis indicated that a lifetime benefit cap of $500,000 for treatment of psoriasis starting at age 20 years exhausted around the age of 40 years. Furthermore, an annual cap of $1000 allowed for full coverage of only methotrexate while, annual caps of $15,000 or less affected coverage for etanercept and efalizumab. For patients requiring multiple drug treatments, even higher annual caps limited drug coverage. CONCLUSIONS: Annual and lifetime limits were most common form of caps. Insurance limits potentially affect access to health care as they limit coverage of treatments for psoriasis and potentially other conditions. It is important for physicians to be aware of the variations in insurance coverage, especially before a new treatment option is explored. If insurance coverage was a standard question in the doctor-patient encounter, it could arguably improve patient compliance and outcomes.
PSK4

MEDICATION-RELATED FACTORS AFFECTING HEALTH CARE OUTCOMES AND COSTS IN PATIENTS WITH PSORIASIS AND ACNE IN THE UNITED STATES
Kulkarni AS 1 , Balkrishnan R 1 , Feldman SR 2 1 The Ohio State University College of Pharmacy, Columbus, OH, USA, 2 Wake Forest University School of Medicine, Winston Salem, NC, USA OBJECTIVES: Comparing relationships between health status and costs and medication related factors in the treatment of acne and psoriasis. METHODS: This was a cross sectional study comparing cohorts of acne and psoriasis patients, using the United States Medical Expenditure Panel Survey (MEPS) 2000 database. Patients were identified using the ICD-9 (International Classification of Diseases, 9th revision) code "706" for acne vulgaris and "696" for psoriasis and similar conditions. ICD-9 codes for acne/psoriasis and receipt of medication for acne/psoriasis were used in obtaining records of medical events. Costs, demographics information, health care service utilization and clinical patient variables were retrieved from the MEPS database. Health status information was obtained using the EuroQOL (EQ-5D) scores available in MEPS. Indices for medication adherence and comorbidities were also calculated using the data from the MEPS. Separate weighted multivariate linear regression analysis was performed on data for approximately 5 million acne patients and 1 million psoriasis patients (weighted sample size). RESULTS: Acne-related medication accounted for approximately 36% of the total acne related health care costs, while psoriasis-related medications accounted for almost 50% of the total psoriasis related health care costs. Both acne and psoriasis patients had an average of almost 3 annual prescription refills. Use of topical corticosteroid therapy was associated with decrease in psoriasisspecific health care costs (p = 0.022) and better health status (P < 0.01). Increased office based visits resulted in higher acne and psoriasis related health care costs (p < 0.01). Increased number of refills of acne specific drugs and oral contraceptive use was associated with an improvement in health status (p < 0.05). CONCLUSIONS: Use of controller medications in psoriasis, most notably topical corticosteroids is the primary driver of reduced health care costs and better health status. Contrary to popular belief, pharmacological treatment of acne does not significantly add to acne-related health care costs.
PSK5 TREATMENT PATTERNS IN PATIENTS WITH SEVERE PSORIASIS
Kulkarni AS 1 , Horn E 2 , Balkrishnan R 1 , Feldman SR 3 1 The Ohio State University College of Pharmacy, Columbus, OH, USA, 2 National Psoriasis Foundation, Portland, OR, USA, 3 Wake Forest University School of Medicine, Winston Salem, NC, USA OBJECTIVES: This study examined if patients with severe psoriasis were treated in accordance with therapy/medications as per guidelines recommended by the American Academy of Dermatology (AAD) (i.e. receive either phototherapy or systemic treatment). METHODS: A survey for this study was conducted by the National Psoriasis Foundation between November and December 2004. Respondents, screened for a mix of gender and age, were interviewed over the phone (n = 188) and by online surveys (n = 212). Information on current medication use was obtained. Self-reported Body Surface Area (BSA) involvement was used to measure severity of psoriasis. BSA of greater than 10% is indicative of severe psoriasis. Severity was also assessed more globally using the Koo-Mentor Psoriasis Index (KMPI). KMPI scores of 50 and above are suggestive of significant negative health related quality of life and warrant initiation of systemic therapy. Cross sectional nature of this study permitted analysis of patients with severe psoriasis only. Descriptive data were generated to determine demographic characteristics of study population and prescription patterns. RESULTS: Approximately 55% of the population had severe psoriasis as measured by BSA, while 75% had severe psoriasis as per KMPI scores. About 19% of the study population indicated that they were currently not on any treatment. Almost 15% of the patients with severe psoriasis identified with BSA (n = 212) and KMPI (n = 299) were on some form of topical therapy alone to treat their psoriasis (i.e. they were not treated in accordance to the AAD guidelines.). CONCLUSIONS: AAD guidelines provide a standard for psoriasis treatment options and conditions for their prescriptions. Even with such easily accessible guidelines in place, this study has shown that there are several people suffering from severe psoriasis that are not on recommended therapy. 
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